ReviewCurrent opinion in virology2025
Virological and immunological determinants of hepatitis E virus infection outcomes.
Review in Current opinion in virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low HBV replication does not aggravate disease progression in patients with superinfection with HEV.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide, especially in regions with limited sanitation infrastructure. Unlike hepatitis B virus (HBV) and hepatitis C virus (HCV) - which frequently progress to chronic infections associated with cirrhosis and hepatocellular carcinoma - HEV typically leads to acute and self-resolving infection in immunocompetent individuals. This review explores the mechanistic underpinnings that distinguish HEV's clinical trajectory from HBV and HCV, focusing on viral genome organization, replication strategies, immune evasion tactics, and host immune responses. Understanding these factors provides critical insights into the determinants of viral clearance versus persistence and may guide future vaccine and antiviral development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.